- The mixture of real-life information units in uncommon illnesses with revolutionary massive information/synthetic intelligence/novel scientific computational data will remodel biomedical analysis, product improvement, and remedy.
- Real-life information and Innovative Bioinformatic Algorithms (RIBA mission) will allow the creation of a robust setting to speed up, de-risk, and enhance the event of latest orphan medication for a lot of illnesses and illness areas.
- RIBA develops and presents data-/computing-driven options to information the very best and most exact innovation for a brand new means of drug improvement in a contemporary biopharmaceutical setting.
- The collaboration will begin with Epilepsy as the primary indication
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and HEIDELBERG, Germany, July 27, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage firm centered on uncommon illnesses that transforms real-world scientific and genetic information into actionable info for sufferers, physicians, and pharmaceutical corporations, and Molecular Health, a number one firm within the discipline of knowledge and computing science for precision medication, introduced at this time that they’ll collaborate solely to provoke the Real-life information and Innovative Bioinformatic Algorithms (RIBA) mission – beginning with Epilepsy as the primary indication. RIBA goals to foster a singular novel precision medication setting to speed up, de-risk, and enhance the event of latest orphan medication based mostly on the mix of enormous real-life information units in uncommon illness with revolutionary massive information, revolutionary synthetic intelligence, in addition to computational algorithms and experience. Both corporations are satisfied that this technique of merging real-life information with a world curated biomedical data, in addition to making use of synthetic intelligence and scientific computing will seriously change and remodel biomedical analysis, product improvement, and remedy. Additionally, it’s going to provide data-/computing-driven options to information the very best and most exact innovation for the brand new means of drug improvement in a contemporary biopharmaceutical setting.
Prof. Arndt Rolfs, CENTOGENE Chief Executive Officer, said, “We are excited about this collaboration. Both companies have been analyzing the potential interaction for an extended period of time and are deeply convinced that now is the right time to start an exclusive cooperation focusing on rare genetic diseases. The complementary expertise and knowledge of both companies will allow us to reduce the time to develop a new orphan drug by combining of real-life data and innovative computational biomedical expertise. CentoMD®, one of the world’s largest rare disease data repositories, allows us to take advantage of the high quality of the real-life data from a global cohort of more than 500,000 consented patients. The extraordinary expertise of Molecular Health will not only speed up the identification of new targets in rare disease, but also allow us to de-risk and accelerate the development of new orphan drugs.”
“By starting this exciting collaboration between our companies, we are initiating and building a unique novel model of personalized healthcare. The combination of both companies’ data and expertise will ultimately transform modern drug development and therapy. It will allow for the development of better drugs with higher specificity and safety, lower attrition rates in clinical studies, and a faster time to market to help patients with severe diseases worldwide through novel therapies,” stated Dr. Friedrich von Bohlen, Molecular Health Chief Executive Officer. “Together with CENTOGENE, Molecular Health´s deep scientific, medical, and computational expertise will lay the fundament for personalized healthcare options in rare diseases to fulfill the promise of precision medicine.”
The corporations have agreed to begin with Epilepsy as the primary indication. Financial particulars weren’t disclosed.
CENTOGENE engages in analysis and analysis round uncommon illnesses reworking real-world scientific and genetic information into actionable info for sufferers, physicians, and pharmaceutical corporations. Our purpose is to carry rationality to remedy choices and to speed up the event of latest orphan medication by utilizing our intensive uncommon illness data, together with epidemiological and scientific information, in addition to revolutionary biomarkers. CENTOGENE has developed a world proprietary uncommon illness platform based mostly on our real-world information repository with roughly 3.zero billion weighted information factors from over 530,000 sufferers representing over 120 completely different nations as of March 31, 2020.
The Company’s platform contains epidemiologic, phenotypic, and genetic information that displays a world inhabitants, and in addition a biobank of those sufferers’ blood samples. CENTOGENE believes this represents the one platform that comprehensively analyzes multi-level information to enhance the understanding of uncommon hereditary illnesses, which may help within the identification of sufferers and enhance our pharmaceutical companions’ potential to carry orphan medication to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical companions overlaying over 45 completely different uncommon illnesses.
About Molecular Health
Molecular Health is an information science-focused synthetic intelligence computing firm enabling and bettering resolution making in precision medication for healthcare organizations. The firm choices are based mostly on the seize, curation, integration, and evaluation of enormous biomedical and drug information units and mixing them with novel synthetic intelligence and machine studying (AI/ML) applied sciences.
For greater than a decade, the corporate has been creating Dataome, a singular high-quality curated, interoperable system that mixes clinico-molecular and drug information with proprietary analytical processes. Dataome – stand alone or together with buyer information – allows the unlocking of actionable intelligence on the molecular degree to a) enhance analysis and remedy choices by physicians and sufferers; b) enrich and help higher drug discovery, drug improvement, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) extra precisely predict the chance of success and chance of approval of drug candidates in scientific improvement for higher trial prioritization and useful resource and funding allocation. For extra info, go to www.molecularhealth.com.
Important Notice and Disclaimer
This press launch accommodates statements that represent “forward looking statements” as that time period is outlined within the United States Private Securities Litigation Reform Act of 1995, together with statements that categorical the Company’s opinions, expectations, beliefs, plans, targets, assumptions or projections concerning future occasions or future outcomes, in distinction with statements that replicate historic information. Examples embrace dialogue of our methods, financing plans, development alternatives and market development. In some instances, you possibly can establish such forward-looking statements by terminology comparable to “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the detrimental of those phrases or comparable expressions. Forward wanting statements are based mostly on administration’s present beliefs and assumptions and on info at the moment accessible to the Company. However, these forward-looking statements aren’t a assure of our efficiency, and you shouldn’t place undue reliance on such statements. Forward-looking statements are topic to many dangers, uncertainties and different variable circumstances, comparable to detrimental worldwide financial circumstances and ongoing instability and volatility within the worldwide monetary markets, the consequences of the COVID-19 pandemic on our enterprise and outcomes of operations, doable adjustments in present and proposed laws, rules and governmental insurance policies, pressures from growing competitors and consolidation in our business, the expense and uncertainty of regulatory approval, together with from the U.S. Food and Drug Administration, our reliance on third events and collaboration companions, together with our potential to handle development and enter into new consumer relationships, our dependency on the uncommon illness business, our potential to handle worldwide enlargement, our reliance on key personnel, our reliance on mental property safety, fluctuations of our working outcomes as a result of impact of alternate charges or different elements. Such dangers and uncertainties could trigger the statements to be inaccurate and readers are cautioned to not place undue reliance on such statements. Many of those dangers are exterior of the Company’s management and will trigger its precise outcomes to vary materially from these it thought would happen. The forward-looking statements included on this press launch are made solely as of the date hereof. The Company doesn’t undertake, and particularly declines, any obligation to replace any such statements or to publicly announce the outcomes of any revisions to any such statements to replicate future occasions or developments, besides as required by legislation.
For additional info, please confer with the Risk Factors part in our Annual Report for the 12 months ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020 and different present studies and paperwork filed with the U.S. Securities and Exchange Commission (SEC). You could get these paperwork by visiting EDGAR on the SEC web site at www.sec.gov.
Media Contact: CENTOGENE Melissa Hall Corporate Communications Molecular Health GmbH Thomas König Head of Communications & PR FTI Consulting Bridie Lawlor +1.917.929.5684